AlloSource’s commitment to improve and provide safe, quality tissue products to our clinicians is the cornerstone of our clinical research program. The AlloSource Investigator Initiated Research (IIR) Program was established to support investigator initiated research that honors the gift of donation by maximizing its medical impact.
AlloSource accepts proposals for clinical studies of AlloSource tissue and/or post-market product lines. All proposals are reviewed by the AlloSource Research Review Committee (ARRC) and, if approved, AlloSource will collaborate with the Investigator. Grant requests may include project funding and/or implantable tissue.
Submitting a Request
Requests are submitted to the AlloSource Office of Clinical Research, in the Corporate Compliance Department. A Research Request Form, containing as much detail as possible, must be completed for the ARRC to make an evaluation regarding funding or support. See link above for the form.
The AlloSource Research Review Committee (ARRC) meets on a quarterly basis to review all requests based on scientific, medical and/or scholarly significance, as well as alignment with corporate research priorities and available resources. All submissions must be received by the end of the preceding quarter to be eligible for review. All requestors are notified of the committee’s decision, or the status of their submission, after each meeting.
Upon approval of a request, AlloSource will collaborate with the Investigator/site, as a resource, to strengthen the scientific merit of the subsequent study documents and to ensure final study documents reflect the approved proposal.
Requirements for IIR
AlloSource requires the following completed documentation before an approved study can commence:
- Fully executed Research Sponsorship Agreement
- IRB/Ethics Committee approval
- IRB approved informed consent form (ICF)
- Final study protocol
- Final case report forms (CRFs)/data collection spreadsheets
- Quality of Life assessment templates (if applicable)
- AlloSource approved Adverse Event/Serious Adverse Event Form
- Curricula Vitae of Investigator(s) (Renewed every 2 years or as necessary by date of expiration)
- Current State Medical License of Investigator(s) (Renewed annually or as necessary by date of expiration)
- Delegation of Authority Log
- Proof of ClinicalTrials.gov acceptance and NCT Number
- IRS W9 Form
AlloSource requires study status updates. Frequency is determined based on study design and complexity. Updates are expected to include information on enrollment (if applicable), study milestones and/or completion dates and white paper/publication status (as appropriate).
- AlloSource requires notification, and rights of approval, of any proposed amendment to the approved protocol, ICF and CRF’s after the research has begun.
- AlloSource reserves the option to include the right to audit sites, generate data queries and asses that all applicable FDA regulations and ICH GCP Guidelines are being met.
In accordance with AlloSource’s Research Sponsorship Agreement, upon study completion Investigators are required to provide the following information:
- Certification that the study was conducted per the study design
- Written report, or raw data, of the final study results
- Draft of white paper/article proposal in advance of submission to publication
- Documentation/proof that grant funds and/or tissue were used solely to conduct the study as designed
- Confirmation of safety reporting
In accordance with AlloSource’s Research Sponsorship Agreement, the Principal Investigator must submit a draft of the white paper/article proposal in advance of submission to a publication or publishing to the Office of Clinical Research. Submissions must comply with all International Committee of Medical Journal Editors (ICMJE) recommendations (“The Uniform Requirements”), www.icmje.org.